Aclarion (NASDAQ:ACON) Rating Lowered to Sell at Wall Street Zen

Aclarion (NASDAQ:ACON) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Aclarion has an average rating of “Sell”.

Aclarion Trading Down 0.4%

Aclarion stock opened at $2.58 on Friday. The business’s 50 day simple moving average is $4.58 and its 200 day simple moving average is $6.40. Aclarion has a 12 month low of $2.34 and a 12 month high of $229.50. The company has a market cap of $2.19 million, a price-to-earnings ratio of -0.17 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last issued its earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.64) by ($0.29). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Aclarion had a negative net margin of 10,908.50% and a negative return on equity of 67.53%. As a group, equities research analysts forecast that Aclarion will post -263.33 earnings per share for the current fiscal year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.